GBDC Stock +24.76% Since The Golden Star Was Identified GBDC Stock +24.76% Since The Golden Star Was Identified Unlock Golden Star List

Range Low Price High Price Comment
30 days $0.0200 $0.0500 Thursday, 18th Apr 2024 CALA stock ended at $0.0251. This is 37.38% less than the trading day before Wednesday, 17th Apr 2024. During the day the stock fluctuated 0% from a day low at $0.0251 to a day high of $0.0251.
90 days $0.0200 $0.120
52 weeks $0.0100 $0.500

Historical Calithera Biosciences prices

Date Open High Low Close Volume
2024-04-18 $0.0251 $0.0251 $0.0251 $0.0251 1 075
2024-04-17 $0.0200 $0.0400 $0.0200 $0.0400 5 257
2024-04-16 $0.0500 $0.0500 $0.0500 $0.0500 0
2024-04-15 $0.0200 $0.0500 $0.0200 $0.0500 1 472
2024-04-12 $0.0200 $0.0200 $0.0200 $0.0200 0
2024-04-11 $0.0200 $0.0200 $0.0200 $0.0200 2 023
2024-04-10 $0.0200 $0.0200 $0.0200 $0.0200 0
2024-04-09 $0.0200 $0.0200 $0.0200 $0.0200 292
2024-04-08 $0.0301 $0.0301 $0.0301 $0.0301 3 548
2024-04-05 $0.0251 $0.0251 $0.0251 $0.0251 101
2024-04-04 $0.0200 $0.0200 $0.0200 $0.0200 0
2024-04-03 $0.0200 $0.0200 $0.0200 $0.0200 867
2024-04-02 $0.0200 $0.0200 $0.0200 $0.0200 0
2024-04-01 $0.0200 $0.0200 $0.0200 $0.0200 561
2024-03-28 $0.0246 $0.0246 $0.0246 $0.0246 163
2024-03-27 $0.0200 $0.0200 $0.0200 $0.0200 1 281
2024-03-26 $0.0200 $0.0200 $0.0200 $0.0200 0
2024-03-25 $0.0200 $0.0200 $0.0200 $0.0200 1 096
2024-03-22 $0.0251 $0.0251 $0.0251 $0.0251 0
2024-03-21 $0.0251 $0.0251 $0.0251 $0.0251 0
2024-03-20 $0.0251 $0.0251 $0.0251 $0.0251 0
2024-03-19 $0.0251 $0.0251 $0.0251 $0.0251 365
2024-03-18 $0.0200 $0.0200 $0.0200 $0.0200 0
2024-03-15 $0.0200 $0.0200 $0.0200 $0.0200 453
2024-03-14 $0.0200 $0.0200 $0.0200 $0.0200 5 628
Click to get the best stock tips daily for free!

About Calithera Biosciences

Calithera Biosciences Calithera Biosciences, Inc., a clinical-stage bio-pharmaceutical company, focuses on the discovery and development of small molecule compounds for tumor metabolism and tumor immunology targets for the treatment of cancer in the United States. The company offers INCB001158, an orally bioavailable arginase inhibitor of arginase that is in Phase 1/2 clinical trial for the treatment of hematology and oncology. It is developing CB-280, an oral arginas... CALA Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT